- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01692301
Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension
A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentina, C1440AAD
- Novartis Investigative Site
-
Ramos Mejia, Buenos Aires, Argentina, B1704ETD
- Novartis Investigative Site
-
-
Santa Fe
-
Rosario, Santa Fe, Argentina, S2000CXH
- Novartis Investigative Site
-
-
-
-
-
Barranquilla, Colombia
- Novartis Investigative Site
-
-
Atlantico
-
Barranquilla, Atlantico, Colombia
- Novartis Investigative Site
-
-
-
-
-
Paris, France, 75015
- Novartis Investigative Site
-
-
-
-
-
Berlin, Germany, 10117
- Novartis Investigative Site
-
Nuernberg, Germany, 90471
- Novartis Investigative Site
-
-
-
-
-
Athens, Greece, 11526
- Novartis Investigative Site
-
Athens, Greece, 11525
- Novartis Investigative Site
-
Thessaloniki, Greece, 54642
- Novartis Investigative Site
-
-
-
-
BG
-
Treviglio, BG, Italy, 24047
- Novartis Investigative Site
-
-
PI
-
Pisa, PI, Italy, 56126
- Novartis Investigative Site
-
-
UD
-
San Daniele Del Friuli, UD, Italy, 33038
- Novartis Investigative Site
-
-
-
-
Tochigi
-
Shimotsuke-city, Tochigi, Japan, 329-0498
- Novartis Investigative Site
-
-
-
-
Gyeonggi-do
-
Bucheon, Gyeonggi-do, Korea, Republic of, 424-717
- Novartis Investigative Site
-
-
Korea
-
Seoul, Korea, Korea, Republic of, 110 744
- Novartis Investigative Site
-
-
-
-
-
Moscow, Russian Federation, 117198
- Novartis Investigative Site
-
Moscow, Russian Federation, 119992
- Novartis Investigative Site
-
Moscow, Russian Federation, 101990
- Novartis Investigative Site
-
Saint Petersburg, Russian Federation, 197022
- Novartis Investigative Site
-
Saint-Petersburg, Russian Federation, 197341
- Novartis Investigative Site
-
Yaroslavl, Russian Federation, 150047
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spain, 28041
- Novartis Investigative Site
-
Madrid, Spain, 28034
- Novartis Investigative Site
-
-
Andalucia
-
Sevilla, Andalucia, Spain, 41071
- Novartis Investigative Site
-
-
Cadiz
-
Jerez de La Frontera, Cadiz, Spain, 11407
- Novartis Investigative Site
-
-
Cataluna
-
Barcelona, Cataluna, Spain, 08003
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spain, 08025
- Novartis Investigative Site
-
Terrassa, Catalunya, Spain, 08221
- Novartis Investigative Site
-
-
Cataluña
-
Centelles, Cataluña, Spain, 08540
- Novartis Investigative Site
-
-
Comunidad Valenciana
-
Puerto de Sagunto, Comunidad Valenciana, Spain, 46520
- Novartis Investigative Site
-
-
Galicia
-
La Coruna, Galicia, Spain, 15706
- Novartis Investigative Site
-
-
-
-
-
Taichung, Taiwan, 40447
- Novartis Investigative Site
-
Taipei, Taiwan, 114
- Novartis Investigative Site
-
-
Taiwan, ROC
-
Taipei, Taiwan, ROC, Taiwan, 112
- Novartis Investigative Site
-
-
-
-
Florida
-
Clearwater, Florida, United States, 33756
- Novartis Investigative Site
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Novartis Investigative Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21204
- Novartis Investigative Site
-
-
Mississippi
-
Belzoni, Mississippi, United States, 39038
- Novartis Investigative Site
-
Jackson, Mississippi, United States, 39209
- Novartis Investigative Site
-
-
Missouri
-
St. Louis, Missouri, United States, 63141
- Novartis Investigative Site
-
-
New York
-
Buffalo, New York, United States, 14215
- Novartis Investigative Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45224
- Novartis Investigative Site
-
-
Texas
-
Houston, Texas, United States, 77081
- Novartis Investigative Site
-
Lake Jackson, Texas, United States, 77566
- Novartis Investigative Site
-
Pasadena, Texas, United States, 77504
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Male and female patients ≥ 60 years of age.
- Patients with essential hypertension, untreated or currently taking antihypertensive therapy.
- Untreated patients must have an office msSBP ≥150 mmHg and <180 mmHg at Visit 101 and Visit 201 if they are newly diagnosed or have not been treated with antihypertensive drugs for the 4 weeks prior to Visit 1.
- Treated patients must have an office msSBP ≥140 mmHg and <180 mmHg at Visit 102 (or Visit 103) and msSBP ≥150 mmHg and <180 mmHg at Visit 201 if they have been treated with antihypertensive drugs for the 4 weeks prior to Visit 1.
- All patients must have pulse pressure >60 mmHg at Visit 201. Pulse pressure is defined as msSBP- msDBP.
- Patients must have a difference in msSBP within +/-15 mmHg between Visit 201 (randomization) and the visit immediately prior to Visit 201.
Key Exclusion Criteria:
- Malignant or severe hypertension (grade 3 of WHO classification; msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg)
- History of angioedema, drug-related or otherwise.
- History or evidence of a secondary form of hypertension, including but not limited to any of the following: renal parenchymal hypertension, renovascular hypertension (unilateral or bilateral renal artery stenosis), coarctation of the aorta, primary hyperaldosteronism, Cushing's disease, pheochromocytoma, polycystic kidney disease, and drug-induced hypertension.
- Transient ischemic cerebral attack (TIA) during the 12 months prior to Visit 1 or any history of stroke.
- History of myocardial infarction, coronary bypass surgery or any percutaneous coronary intervention (PCI) during the 12 months prior to Visit 1.
- History of atrial fibrillation or atrial flutter during the 3 months prior to Visit 1, or active atrial fibrillation or atrial flutter on the ECG at screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LCZ696 (sacubitril/valsartan)
Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period.
At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24.
To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.
|
200 mg tablet
Other Names:
LCZ696 Matching Placebo tablet
Olmesartan matching placebo capsule
amlodipine 2.5 mg or 5 mg tablets
hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
|
ACTIVE_COMPARATOR: Olmesartan
Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period.
At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24.
To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.
|
LCZ696 Matching Placebo tablet
amlodipine 2.5 mg or 5 mg tablets
hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
20 mg and 40 mg capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks
Time Frame: baseline, 12 weeks
|
Central aortic blood pressure was derived from peripheral pressure waveforms recorded noninvasively from the brachial artery using a cuff-based device. This technique uses the brachial pressure and a signal processing algorithm to transform brachial signals into central blood pressure (BP) waveforms. When the aortic pressure waveform was derived, key pulse wave analysis (PWA) parameters, such as CASP was calculated by the system software. At the first study visit, the arm with the highest systolic blood pressure (SBP) was used for all subsequent PWA. Brachial PWA measurements were performed on the same arm that the office blood pressures were taken. Two pulse waveform measurements, meeting all quality control criteria were captured at baseline and at week 12 visits. |
baseline, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Mean Central Pulse (CPP) Pressure
Time Frame: Baseline, 12 weeks, and 52 weeks
|
Baseline, 12 weeks, and 52 weeks
|
|
Change From Baseline in Mean Pulse Wave Velocity (PWV)
Time Frame: baseline, 12 weeks, and 52 weeks
|
Pulse wave velocity recordings were performed on patient while in a supine, face-up position. Tonometry was performed on the carotid simultaneously with the cuff inflation over the femoral artery. Two pulse wave velocity measures, meeting all quality control criteria were captured at baseline, week 12 and week 52. |
baseline, 12 weeks, and 52 weeks
|
Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 52 Weeks
Time Frame: baseline, 52 weeks
|
Central aortic blood pressure was derived from peripheral pressure waveforms recorded noninvasively from the brachial artery using a cuff-based device. This technique uses the brachial pressure and a signal processing algorithm to transform brachial signals into central blood pressure (BP) waveforms. When the aortic pressure waveform was derived, key pulse wave analysis (PWA) parameters, such as CASP was calculated by the system software. At the first study visit, the arm with the highest systolic blood pressure (SBP) was used for all subsequent PWA. Brachial PWA measurements were performed on the same arm that the office blood pressures were taken. Two pulse waveform measurements, meeting all quality control criteria were captured at baseline and at week 12 visits. |
baseline, 52 weeks
|
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
Time Frame: baseline, 12 weeks, and 52 weeks
|
At the first study visit, the patient had his/her blood pressure (BP) measured in both arms; the arm in which the highest sitting SBP was found was used for all subsequent readings throughout the study.
At each study visit, after the patient had been sitting for 5 minutes, SBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff.
The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.
|
baseline, 12 weeks, and 52 weeks
|
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
Time Frame: baseline, 12 weeks, and 52 weeks
|
At the first study visit, the patient had his/her blood pressure (BP) measured in both arms; the arm in which the highest sitting SBP was found was used for all subsequent readings throughout the study.
At each study visit, after the patient had been sitting for 5 minutes, DBP were measured 3 times using a standard mercury sphygmomanometer and appropriate size cuff.
The repeat sitting measurements were made at 1- to 2-minute intervals and the mean of those 3 measurements was used as the average sitting office BP for that visit.
|
baseline, 12 weeks, and 52 weeks
|
Change From Baseline in Mean Sitting Pulse Pressure (msPP)
Time Frame: baseline, 12 weeks, and 52 weeks
|
Mean sitting pulse pressure for each patient and visit was calculated as the difference between the calculated values of mean sitting systolic blood pressure and mean sitting diastolic blood pressure.
|
baseline, 12 weeks, and 52 weeks
|
Change From Baseline in Mean Arterial Pressure (MAP)
Time Frame: baseline, 12 weeks, and 52 weeks
|
Mean arterial pressure (MAP) was calculated from mean sitting systolic BP (msSBP) and mean sitting diastolic BP (msDBP) as (2 * msDBP + msSBP)/3.
|
baseline, 12 weeks, and 52 weeks
|
Change From Baseline in Mean 24-hour Systolic Blood Pressure (maSBP)
Time Frame: Baseline, 12 weeks, and 52 weeks
|
An Ambulatory Blood Pressure Monitor (ABPM) measured a participant's blood pressure over a 24 hour period using an automated validated monitoring device at baseline, week 12 and at week 52 starting one day before each visit.
The 24 hour maSBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24 hour period.
|
Baseline, 12 weeks, and 52 weeks
|
Change From Baseline in Mean 24-hour Diastolic Blood Pressure (maDBP)
Time Frame: Baseline, 12 weeks, and 52 weeks
|
An Ambulatory Blood Pressure Monitor (ABPM) measured a participant's blood pressure over a 24 hour period using an automated validated monitoring device at baseline, week 12 and at week 52 starting one day before each visit.
The 24 hour maDBP was calculated by taking the mean of all ambulatory systolic blood pressure readings for the 24 hour period.
|
Baseline, 12 weeks, and 52 weeks
|
Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (maPP)
Time Frame: Baseline, 12 weeks, and 52 weeks
|
Mean 24 hour ambulatory pulse pressure was calculated as the difference between the mean 24 hour systolic and diastolic ambulatory blood pressure in corresponding visits i.e. baseline, week 12 and week 52.
|
Baseline, 12 weeks, and 52 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Amlodipine
- Valsartan
- Olmesartan
- Olmesartan Medoxomil
- Hydrochlorothiazide
- Sacubitril and valsartan sodium hydrate drug combination
Other Study ID Numbers
- CLCZ696A2216
- 2012-002899-14 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Recruiting
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on LCZ696
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedHeart Failure and Reduced Ejection FractionUnited States
-
Novartis PharmaceuticalsCompletedHypertensionUnited States, Spain, Philippines, Guatemala, Russian Federation, Argentina, Puerto Rico
-
Novartis PharmaceuticalsCompletedChronic Heart Failure With Reduced Ejection FractionBelgium, Estonia, Denmark, Greece, United Kingdom, Germany, Latvia, Lithuania, Spain, Netherlands, Bulgaria, Finland, Poland, Czechia, Iceland, Sweden, France, Ireland, Norway
-
Novartis PharmaceuticalsCompletedChronic Heart Failure (CHF)Spain, Croatia, Taiwan, Germany, Italy, United States, Australia, Netherlands, Switzerland, Belgium, United Kingdom, Bulgaria, Lithuania, Russian Federation, France, Argentina, Korea, Republic of, Poland, Canada, Turkey
-
Novartis PharmaceuticalsCompletedChronic Heart Failure With Reduced Ejection FractionGermany
-
University Hospital, MontpellierCompletedChronic Heart Failure | Sleep Apnea SyndromeFrance
-
Novartis PharmaceuticalsCompletedEssential HypertensionChina, Korea, Republic of, Taiwan, Hong Kong, Thailand, Philippines, Singapore
-
Novartis PharmaceuticalsCompletedHeart Failure With Reduced Ejection Fraction (HF-rEF)Japan
-
Novartis PharmaceuticalsCompletedPediatric Heart FailureUnited States, Italy, Croatia, Japan, Saudi Arabia, Spain, Austria, Korea, Republic of, Germany, Thailand, Canada, Bulgaria, India, Russian Federation, Turkey, France, Switzerland, China, Taiwan, Lebanon, Poland, Argentina, Hungary, P... and more